Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Christoph Meyenberg
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer
JAMA Oncology
Cancer Research
Oncology
Related publications
Resource Utilization and Cost Saving Analysis of Subcutaneous Versus Intravenous Trastuzumab in Early Breast Cancer Patients
Oncotarget
Oncology
Pcn75 - Budget Impact Model of Subcutaneous Trastuzumab Compared With Intravenous Trastuzumab on the Treatment of Her-2 Positive Breast Cancer in the Brazilian Private Healthcare System
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
NT-proBNP Correlates With LVEF Decline in HER2-positive Breast Cancer Patients Treated With Trastuzumab
Cardio-Oncology
Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History
Nowotwory
Cancer Research
Oncology
Women With Early Breast Cancer to Be Tested for Trastuzumab Treatment
BMJ
Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine
Medicine
Trastuzumab in Combination With Metronomic Cyclophosphamide and Methotrexate in Patients With HER-2 Positive Metastatic Breast Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines
BMC Health Services Research
Health Policy
Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study
Oncologist
Cancer Research
Medicine
Oncology
